Immune thrombocytopenia: options and new perspectives.
Blood Coagul Fibrinolysis
; 32(7): 427-433, 2021 Oct 01.
Article
in English
| MEDLINE | ID: covidwho-20233854
ABSTRACT
Immune thrombocytopenia is a haematological, autoimmune disorder characterized by elevated platelet demolition due to the presence of antiplatelet autoantibodies derived from B cells and to an irregular, deficient process of platelets production in bone marrow. In this review, after a brief presentation of 'old' strategies used nowadays yet, we focused on new drugs used in the treatment of immune thrombocytopenia and their mechanism of action and posology, basing on the last scientific literature. The observation that CoViD-19 can be associated with immune thrombocytopenia is also put in evidence. Particular attention will be dedicated on the concept that the ideal treatment should represent a solution not only for the failure of normal processes of production and survival of platelets, but also it should improve quality of life of patients, with minimum adverse events. Anyway, despite enormous advances of the last years, further investigations are necessary in order to define scrupulously long-term efficacy of new molecules proposed.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Purpura, Thrombocytopenic, Idiopathic
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Blood Coagul Fibrinolysis
Journal subject:
Vascular Diseases
/
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
MBC.0000000000001058
Similar
MEDLINE
...
LILACS
LIS